Compare Mercadolibre Inc (MELI) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mercadolibre Inc vs Merck & Co., Inc. — how do they compare? Mercadolibre Inc trades at $1,888.73 (market cap $98.35B), while Merck & Co., Inc. trades at $132.37 (market cap $321.77B). The key difference: Merck & Co., Inc. is far larger — about 3.3× Mercadolibre Inc's market cap, and Merck & Co., Inc. pays a 2.61% dividend while Mercadolibre Inc pays none. Which is the better fit depends on your goals.
| MELI | MRK | |
|---|---|---|
Market Cap | $98.35B | $321.77B |
Sector | Consumer Cyclical | Health |
52-Week High | $2.51K | $131.84 |
52-Week Low | $1.55K | $77.60 |
Enterprise Value | $106.00B | $368.53B |
Dividend Yield | — | 2.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MercadoLibre (MELI) trades at $1,824.34, up 0.2% with a bearish technical signal despite strong fundamentals. The company reported Q2 2026 EPS of $9.19, beating estimates by 6.2%, while revenue grew 50% year-over-year. Operating cash flow reached $12.12 billion in 2025, supporting aggressive growth investments. Analyst consensus remains strongly bullish with a $2,150 price target, though margin compression from strategic spending presents near-term headwinds.
MELI's growth-first strategy drives market share gains but pressures profitability, with net margin declining to 5.3%. The stock offers 18% upside to consensus target but faces execution risk in balancing expansion with returns. Competitive threats from global e-commerce players and Latin American economic volatility require monitoring. Long-term prospects remain positive given ecosystem strength and dominant market position.
Merck (MRK) trades at $130.9, up 1.81% today, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $140.36. Recent earnings beats and a 72.97% gross margin highlight strong profitability, while the acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline. The stock faces headwinds from a high P/E ratio of 104.34 and fluctuating cash flows.
The outlook is positive with robust fundamentals and strategic M&A, but valuation concerns and competitive pressures in pharma pose risks. Upside is likely if earnings growth continues, though investors should monitor debt levels and integration of acquisitions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mercadolibre Inc
MercadoLibre runs the largest e-commerce marketplace in Latin America, connecting a network of more than 140 million active users and 1 million active sellers as of the end of 2021 across an 18-country footprint. The company also operates a host of complementary businesses, with shipping solutions (Mercado Envios), a payment and financing operation (Mercado Pago), advertisements (Mercado Clics), classifieds, and a turnkey e-commerce solution (Mercado Shops) rounding out its arsenal. MercadoLibre generates revenue from final value fees, advertising royalties, payment processing, insertion fees, subscription fees, and interest income from consumer and small-business lending.
Read more on MELI →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
